St. Jude dubs cybersecurity allegations 'false and misleading' and MW responds
Allegations that St. Jude Medical Inc.'s (NYSE: STJ) implantable heart devices have lax cybersecurity leaving the devices vulnerable to attacks are "false and misleading," the company said. Analysts have sided with St. Jude on the issue, for the most part, advising that the stock's short-term sell off based on the Muddy Waters Capital LLC (MW) report was unwarranted.
To co-develop or not; FDA s latest CDx draft
The FDA guidance for companion diagnostic co-development has finally emerged in draft form, and there are a couple of interesting features about it other than that its absence may have kept a few companies on the sidelines. One of the more conspicuous things about the draft is that it suggests that the term co-development may come to mean different things to different stakeholders, not all of them particularly appetizing for industry. (MDD Perspectives)
Doggedly determined Stentys shifts from start-up mode to build on sustained growth
PARIS The third time around proved to be the charm for Paris-based Stentys SA as it reported a 41 percent increase in sales based on what it calls a strong demand for its third-generation stent, the sixth consecutive quarter of growth.